Liver Disease Pandemic: 1.8 Billion Cases Projected by 2050

Top Summary

• What happened: A new study projects that metabolic dysfunction-associated steatotic liver disease (MASLD) will affect 1.8 billion people globally by 2050.
• Why it matters: MASLD, previously known as non-alcoholic fatty liver disease, is rapidly increasing and poses a significant public health challenge, currently impacting one in six people.
• What changes: The rising prevalence necessitates increased awareness, policy changes, and interventions to mitigate the disease's impact and prevent future health complications.
• Who is affected: While older adults are more prone, younger demographics are increasingly affected, with disparities evident across regions and by sex.

Alarming Rise of MASLD

A global study forecasts a sharp increase in metabolic dysfunction-associated steatotic liver disease (MASLD) cases. The condition, formerly known as non-alcoholic fatty liver disease, is expected to affect approximately 1.8 billion individuals worldwide by 2050.

The research, published in The Lancet Gastroenterology & Hepatology, highlights a worrying trend. Currently, MASLD affects one in six people, or about 1.3 billion individuals globally.

Key Drivers and Regional Disparities

The prevalence of MASLD has surged by 143% in the past 30 years. In 1990, around 500 million people lived with the condition, which jumped to 1.3 billion by 2023.

Key factors driving this increase include high blood sugar levels, elevated body mass index (BMI), and smoking habits. These are closely linked to type 2 diabetes and obesity.

Disparities exist across regions, with northern Africa and the Middle East experiencing higher rates.

Impact on Specific Demographics

MASLD is more frequent in men than women, with the highest prevalence in older adults (80 to 84 years). However, the largest case concentrations are among younger individuals, particularly men aged 35 to 39 and women aged 55 to 59.

The study's authors from the Institute for Health Metrics and Evaluation emphasized the increasing prevalence in younger demographics. This reflects changing health and lifestyle patterns.

The UK, US and Australia See Increases

Several countries have seen significant increases in MASLD prevalence. In the UK, the prevalence rose by 33% between 1990 and 2023.

Australia recorded a 30% rise, while the United States saw a 22% increase during the same period, according to The Guardian's analysis.

Stable Health Impact but Future Risks Remain

Despite rising cases, the overall health impact (years lost due to illness or premature death) has remained stable. Advancements in treatment and care may contribute to this.

However, the growing number of cases poses a risk. Many individuals could face severe complications like liver cirrhosis or cancer.

MASLD is often asymptomatic. Symptoms, when present, may include fatigue, malaise, and abdominal discomfort."Recognising MASLD as a global health priority is essential, advocating for policies, awareness campaigns, and interventions aimed at mitigating its impact and preventing future health complications."

What to Watch Next

Future research will likely focus on developing targeted interventions to address the root causes of MASLD, such as obesity and high blood sugar. Public health initiatives and policy changes will be crucial in curbing the projected rise of this disease globally.